Answers are grounded in this paper and cite their sources.
Background Sex-related immunological differences may influence outcomes after lung transplantation, but evidence remains inconsistent. Methods We retrospectively analyzed 252 adults transplanted at the University Hospital Zurich (2015-2024). The primary endpoint was 5-year all-cause mortality; secondary endpoints included acute and chronic rejection, development of donor-specific antibodies (DSA), antibody-mediated rejection (AMR), and post-transplant infectious complications. Results Mean age was 52.2 years. Underlying diagnoses differed by sex (pulmonary fibrosis more common in men, cystic fibrosis in women; p = 0.004). Five-year survival did not differ between sexes (males 56%, females 62%; log-rank p = 0.27) or by donor-recipient sex combination (p = 0.65). Cox regression confirmed that sex and donor-recipient sex interaction were not associated with mortality (recipient sex HR 1.29, 95% CI 0.82-2.03, p = 0.27). Male recipients of female donor lungs had higher rates of de novo DQ-DSA (p = 0.009) and AMR (p = 0.021), whereas female recipients of male lungs more often developed early cellular rejection (p = 0.010). CLAD occurred in 22% without sex-related differences (p=0.316). Infectious complications showed sex-specific bacterial patterns (p = 0.014), with Pseudomonas predominating in males. Conclusion While overall survival was unaffected, sex-specific alloimmune patterns suggest underlying biological differences that warrant further investigation.
No takes yet. Share an insight, caveat, or question.
Rosselli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: